Stock Scorecard

Stock Summary for InflaRx N.V. (IFRX) - $2.04 as of 11/21/2024 3:33:30 AM EST

Total Score

8 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for IFRX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for IFRX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for IFRX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for IFRX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for IFRX (22 out of 90)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0

Latest News for for IFRX

InflaRx Receives Positive CHMP Opinion for GOHIBIC® ( Vilobelimab ) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome - InflaRx ( NASDAQ:IFRX ) 11/15/2024 12:51:00 PM
InflaRx Receives Positive CHMP Opinion for GOHIBIC® ( Vilobelimab ) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome 11/15/2024 12:51:00 PM
InflaRx N.V. ( IFRX ) Reports Q3 Loss, Tops Revenue Estimates 11/8/2024 1:40:00 PM
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update 11/8/2024 12:30:00 PM
Chimerix ( CMRX ) Reports Q3 Loss, Lags Revenue Estimates 11/7/2024 1:35:00 PM
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - Clearside Biomedical ( NASDAQ:CLSD ) 11/4/2024 12:05:00 PM
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress 9/25/2024 11:30:00 AM
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress - InflaRx ( NASDAQ:IFRX ) 9/25/2024 11:30:00 AM
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases 9/3/2024 11:30:00 AM
InflaRx Announces Participation in September Investor Events 8/27/2024 11:30:00 AM

Financial Details for IFRX

Company Overview
Ticker IFRX
Company Name InflaRx N.V.
Country USA
Description InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is headquartered in Jena, Germany.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History
Last Day Price 2.04
Price 4 Years Ago 5.03
Last Day Price Updated 11/21/2024 3:33:30 AM EST
Last Day Volume 370,306
Average Daily Volume 223,220
52-Week High 2.44
52-Week Low 1.17
Last Price to 52 Week Low 74.36%

Valuation Measures
Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -3.43
Free Cash Flow Ratio 4.53
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 5.31
Total Cash Per Share 0.45
Book Value Per Share Most Recent Quarter 1.74
Price to Book Ratio 1.64
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 1,138.78
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 1

Share Statistics
Total Shares Outstanding 58,883,000
Market Capitalization 120,121,320
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -57.78%
Reported EPS 12 Trailing Months -1.04
Reported EPS Past Year -0.71
Reported EPS Prior Year -0.79
Net Income Twelve Trailing Months -54,925,247
Net Income Past Year -42,667,529
Net Income Prior Year -27,042,313
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -2,422.00

Balance Sheet
Total Cash Most Recent Quarter 26,205,938
Total Cash Past Year 12,778,469
Total Cash Prior Year 16,265,355
Net Cash Position Most Recent Quarter 26,205,938
Net Cash Position Past Year 12,778,469
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 102,666,305
Total Stockholder Equity Prior Year 88,349,440
Total Stockholder Equity Most Recent Quarter 65,282,425

Free Cash Flow
Free Cash Flow Twelve Trailing Months -48,864,964
Free Cash Flow Per Share Twelve Trailing Months -0.83
Free Cash Flow Past Year -37,894,066
Free Cash Flow Prior Year -33,905,208

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.09
MACD Signal 0.05
20-Day Bollinger Lower Band 1.27
20-Day Bollinger Middle Band 1.58
20-Day Bollinger Upper Band 1.89
Beta 1.58
RSI 61.70
50-Day SMA 2.34
150-Day SMA 0.00
200-Day SMA 2.69

System
Modified 11/21/2024 3:33:31 AM EST